Cellomics(R), Inc. Delivers Its First Kinetic High Content Screening Platform to Abgenix

Apr 23, 2001, 01:00 ET from Cellomics, Inc.

    PITTSBURGH, April 23 /PRNewswire Interactive News Release/ --
 Cellomics, Inc. announced today that Abgenix, Inc. (Nasdaq:   ABGX) of Fremont,
 CA is the first company to take delivery of Cellomics' new ArrayScan(R)
 Kinetics Automated High Content Screening Workstation.  Abgenix will use the
 system to characterize the effects of its antibody-based therapeutic drug
 candidates on live cells.
     Cellomics and Abgenix are working together on kinetic cell-based screening
 applications for use in early drug discovery.  Cellomics' President and CEO D.
 Lansing Taylor, Ph.D. stated, "Cellomics is very excited about this
 relationship with Abgenix.  Their expertise in antibody-based therapies is a
 perfect complement to Cellomics' kinetic cellular analysis technology.  This
 collaboration will help keep both our companies at the forefront of our
 respective fields."
     The ArrayScan(R) Kinetics (ASK) Workstation is a new platform that allows
 researchers to perform complete, automated high content screening on multiple
 plates of living cells.  The ASK Workstation operates under controlled growth
 conditions with compound delivery where time, or kinetic, information is
 critical.  This enables researchers to test the effects of drug candidates in
 cells at multiple points in time and under various growth conditions to assess
 interaction between drugs and cells or cell components, which may be useful in
 understanding toxicity and efficacy.  This proprietary workstation includes
 many of the features of the ArrayScan(R) II, Cellomics' automated high content
 screening instrument, as well as an advanced plate reader, 30-plate incubator
 stacker, on-board fluid addition, compound storage, and automatic plate
 handling.  ASK applications include measurement of transient signaling
 responses like calcium flux within heterogeneous sub-populations of cells,
 mapping compound effects on complex cellular pathways and processes such as
 apoptosis over time, and time-dependent compound specificity data on multiple
 cellular targets in a pathway simultaneously in a single assay.  The ASK
 Automated HCS Workstation was developed in collaboration with Carl Zeiss Jena.
     Abgenix is a biopharmaceutical company focused on the development and
 commercialization of antibody therapies for a variety of diseases.  The
 company developed XenoMouse(TM) technology to enable the rapid generation of
 high affinity, fully human antibody product candidates to essentially any
 disease target appropriate for antibody therapy.  Abgenix uses its XenoMouse
 technology to build a large and diversified product portfolio through the
 establishment of licensing arrangements with multiple pharmaceutical,
 biotechnology and genomics companies and through the development of its own
 internal proprietary products.
     C. Geoffrey Davis, Ph.D., Chief Scientific Officer for Abgenix, said, "Our
 collaboration with Cellomics will further expand our capabilities in
 developing antibody-based therapies and provide increased value to potential
 alliances with other pharmaceutical company partners.  We are delighted with
 the prospects that are now open to us because of the Cellomics technology."
     Cellomics is developing and commercializing High Content Screening,
 informatics, cellular bioinformatics and other products designed to provide
 customers with in-depth knowledge about cells and cellular functions in order
 to aid research in drug discovery, basic biomedical research and clinical
 diagnostics.  Currently, Cellomics' ArrayScan(R) II High Content Screening
 platforms are in use at multiple sites within eighty percent of the top ten
 pharmaceutical companies in the world, as well as several additional leading
 pharmaceutical and biotechnology companies.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X25518353
 
 

SOURCE Cellomics, Inc.
    PITTSBURGH, April 23 /PRNewswire Interactive News Release/ --
 Cellomics, Inc. announced today that Abgenix, Inc. (Nasdaq:   ABGX) of Fremont,
 CA is the first company to take delivery of Cellomics' new ArrayScan(R)
 Kinetics Automated High Content Screening Workstation.  Abgenix will use the
 system to characterize the effects of its antibody-based therapeutic drug
 candidates on live cells.
     Cellomics and Abgenix are working together on kinetic cell-based screening
 applications for use in early drug discovery.  Cellomics' President and CEO D.
 Lansing Taylor, Ph.D. stated, "Cellomics is very excited about this
 relationship with Abgenix.  Their expertise in antibody-based therapies is a
 perfect complement to Cellomics' kinetic cellular analysis technology.  This
 collaboration will help keep both our companies at the forefront of our
 respective fields."
     The ArrayScan(R) Kinetics (ASK) Workstation is a new platform that allows
 researchers to perform complete, automated high content screening on multiple
 plates of living cells.  The ASK Workstation operates under controlled growth
 conditions with compound delivery where time, or kinetic, information is
 critical.  This enables researchers to test the effects of drug candidates in
 cells at multiple points in time and under various growth conditions to assess
 interaction between drugs and cells or cell components, which may be useful in
 understanding toxicity and efficacy.  This proprietary workstation includes
 many of the features of the ArrayScan(R) II, Cellomics' automated high content
 screening instrument, as well as an advanced plate reader, 30-plate incubator
 stacker, on-board fluid addition, compound storage, and automatic plate
 handling.  ASK applications include measurement of transient signaling
 responses like calcium flux within heterogeneous sub-populations of cells,
 mapping compound effects on complex cellular pathways and processes such as
 apoptosis over time, and time-dependent compound specificity data on multiple
 cellular targets in a pathway simultaneously in a single assay.  The ASK
 Automated HCS Workstation was developed in collaboration with Carl Zeiss Jena.
     Abgenix is a biopharmaceutical company focused on the development and
 commercialization of antibody therapies for a variety of diseases.  The
 company developed XenoMouse(TM) technology to enable the rapid generation of
 high affinity, fully human antibody product candidates to essentially any
 disease target appropriate for antibody therapy.  Abgenix uses its XenoMouse
 technology to build a large and diversified product portfolio through the
 establishment of licensing arrangements with multiple pharmaceutical,
 biotechnology and genomics companies and through the development of its own
 internal proprietary products.
     C. Geoffrey Davis, Ph.D., Chief Scientific Officer for Abgenix, said, "Our
 collaboration with Cellomics will further expand our capabilities in
 developing antibody-based therapies and provide increased value to potential
 alliances with other pharmaceutical company partners.  We are delighted with
 the prospects that are now open to us because of the Cellomics technology."
     Cellomics is developing and commercializing High Content Screening,
 informatics, cellular bioinformatics and other products designed to provide
 customers with in-depth knowledge about cells and cellular functions in order
 to aid research in drug discovery, basic biomedical research and clinical
 diagnostics.  Currently, Cellomics' ArrayScan(R) II High Content Screening
 platforms are in use at multiple sites within eighty percent of the top ten
 pharmaceutical companies in the world, as well as several additional leading
 pharmaceutical and biotechnology companies.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X25518353
 
 SOURCE  Cellomics, Inc.